Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 12/20 | 0.43 |
| ▸ | MAOB | P27338 | 2/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.40 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.40 |
| ▸ | HRH1 | P35367 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25754605 | 1.00 | HRH3 (0.43) | HRH3MAOBKCNH2HRH4HRH1 | |
| SCHEMBL25754613 | 0.87 | HRH3 (0.42) | HRH3MAOBALDH1A1 | |
| SCHEMBL25754615 | 0.84 | HRH3 (0.42) | HRH3KCNH2HRH1ALDH1A1 | |
| SCHEMBL25754610 | 0.84 | HRH3 (0.42) | HRH3KCNH2HRH1ALDH1A1 | |
| SCHEMBL25754725 | 0.84 | KMT2A (0.36) | HRH3KCNH2HRH1KDM4EALDH1A1 | |
| SCHEMBL25754594 | 0.83 | CYP1A2 (0.42) | HRH3KCNH2HRH1KDM4EALDH1A1 | |
| SCHEMBL25754712 | 0.81 | KMT2A (0.38) | KDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL25754592 | 0.80 | ALDH1A1 (0.50) | HRH3KDM4EALDH1A1 | |
| SCHEMBL25754475 | 0.79 | ALDH1A1 (0.36) | HRH3KCNH2HRH1KDM4EALDH1A1 | |
| SCHEMBL22266186 | 0.77 | HRH3 (0.50) | HRH3KCNH2HRH4HRH1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230210999-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | EUBULUS BIOTHERAPEUTICS (HONG KONG) LIMITED (HK) | 2023-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230210999-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | UCHL3, UBE2L3, ADAM33 | HRH3 1596/4885MAOB 2003/4885KCNH2 4842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.